• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Carfilzomib in multiple myeloma
【24h】

Carfilzomib in multiple myeloma

机译：卡非佐米治疗多发性骨髓瘤

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Advances in drug therapy for multiple myeloma (MM) during the previous decade have improved survival outcomes; however, the disease remains incurable as patients eventually relapse or become refractory to all available therapies. Therefore, there is a clear need for more effective and well-tolerated treatments. Areas covered: We review preclinical and clinical data regarding the use of carfilzomib, a proteasome inhibitor that is structurally and mechanistically distinct from bortezomib, for the treatment of MM patients. Carfilzomib pharmacokinetics, pharmacodynamics, efficacy, safety and tolerability are summarized, based on Phase I/II trial data. Expert opinion: Carfilzomib represents a significant advance in the management of relapsed and/or refractory MM patients, including those intolerant or resistant to bortezomib. High response rates have been demonstrated with carfilzomib as a single agent or in combination with alkylating agents, immunomodulators and corticosteroids, even among patients who have failed multiple prior therapies. Carfilzomib also has significant potential in the frontline setting, with encouraging response and survival rates observed for combination regimens. Further evaluation of carfilzomib-containing regimens is ongoing in Phase III trials and investigator-sponsored studies, which include combinations with novel investigational agents. These findings will shape the future role of carfilzomib for MM patients across multiple settings.
机译：简介：在过去的十年中，多发性骨髓瘤（MM）药物治疗的进展提高了生存率;但是，随着患者最终复发或对所有可用疗法均变得顽固，该疾病仍然无法治愈。因此，显然需要更有效和耐受性更好的治疗方法。涵盖的领域：我们审查了有关卡非佐米的临床前和临床数据，卡非佐米是一种蛋白酶体抑制剂，在结构和机械上与硼替佐米不同，用于治疗MM患者。根据I / II期试验数据，总结了卡非佐米的药代动力学，药效学，功效，安全性和耐受性。专家意见：Carfilzomib在复发和/或难治性MM患者（包括对硼替佐米不耐受或耐药的MM患者）的管理方面取得了重大进展。卡非佐米作为单一药物或与烷化剂，免疫调节剂和皮质类固醇合用已显示出高应答率，即使在先前的多种疗法均无效的患者中也是如此。卡非佐米（Carfilzomib）在一线治疗方面也具有显着潜力，在联合用药方案中观察到令人鼓舞的反应和生存率。含卡非佐米的方案的进一步评估正在III期试验和研究者资助的研究中进行，其中包括与新型研究药物的组合。这些发现将影响卡非佐米在多种情况下对MM患者的未来作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号